Mother’s Postpartum Oxycodone Use: No Safer for Breastfed Infants than Codeine
Cincinnati, OH, September 6, 2011 -- Doctors have been prescribing codeine for postpartum pain management for many years and, until recently, it was considered safe to breastfeed while taking the opioid. The death of an infant exposed to codeine through breast milk has many health care providers questioning the safety of the drug when used by breastfeeding mothers. Because of the potential risks, some doctors have begun the practice of prescribing oxycodone as an alternative to codeine. However, a new study soon to be published in The Journal of Pediatrics finds that oxycodone is no safer for breastfed infants than codeine.
To estimate the risks to babies breastfed by mothers taking either codeine or oxycodone, Dr. Gideon Koren of The Hospital for Sick Children (SickKids) in Toronto, and colleagues from institutions in both Canada and The Netherlands, pooled data from the Motherisk Program, a Teratology Information Center at SickKids that counsels women about the safety of using medication during pregnancy and breastfeeding. The researchers surveyed 533 women who had contacted the program with questions about using acetaminophen, codeine, or oxycodone for pain management while breastfeeding.
The mothers were asked to report their experiences with central nervous system (CNS) depression, as well as those of their infants, during the time they were taking one of the drugs and breastfeeding. According to Dr. Koren, “Typical symptoms of CNS depression include sleepiness, lethargy, and – in the infant’s case – trouble breastfeeding.” Of the 210 mothers who took codeine while breastfeeding, 16.7% reported symptoms of CNS depression in their child. Moreover, 20% of the 139 mothers who took oxycodone described these symptoms in their child. In contrast, only 0.5% of the 184 women who took acetaminophen while breastfeeding reported symptoms of CNS depression in their child. Additionally, mothers of symptomatic infants who took either codeine or oxycodone were significantly more likely to report CNS depression symptoms in themselves.
“The strong concordance between maternal and infant symptoms may be used to identify babies at higher risk of CNS depression,” Dr. Koren notes. He suggests that health care providers should perform follow-up examinations on breastfed babies whose mothers are receiving either codeine or oxycodone, and he stresses that these drugs “cannot be considered safe during breastfeeding in all cases.”
The study, reported in “Central Nervous System Depression of Neonates Breastfed by Mothers Receiving Oxycodone for Postpartum Analgesia” by Jessica Lam, BSc, Lauren Kelly, MSc, Catherine Ciszkowski, MSc, Marieke L.S. Landsmeer, MD, Marieke Nauta, MD, Bruce C. Carleton, PharmD, Michael R. Hayden, MD, PhD, Parvaz Madadi, PhD, and Gideon Koren, MD, appears in The Journal of Pediatrics, DOI 10.1016/j.jpeds.2011.06.050, published by Elsevier.
# # #
About The Journal of Pediatrics
The Journal of Pediatrics ( www.jpeds.com) is a primary reference for the science and practice of pediatrics and its subspecialties. This authoritative resource of original, peer-reviewed articles oriented toward clinical practice helps physicians stay abreast of the latest and ever-changing developments in pediatric medicine. The Journal of Pediatrics is ranked 3rd out of 107 pediatric medical journals (2010 Journal Citation Reports, published by Thomson Reuters).
Elsevier is a global information analytics business that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
+1 513 636 7140